We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




New Genetic Tool Analyzes Umbilical Cord Blood to Predict Future Disease

By LabMedica International staff writers
Posted on 29 Apr 2025

Children are experiencing metabolic problems at increasingly younger ages, placing them at higher risk for serious health issues later in life. More...

There is a growing need to identify this risk from birth to enable preventative measures. Now, the umbilical cord may serve as a tool for doctors to predict which children are more likely to face long-term health problems, such as diabetes, stroke, and liver disease. DNA changes found in cord blood could provide early insights into which infants are at higher risk, paving the way for earlier and potentially life-saving interventions, according to research presented at Digestive Disease Week (DDW) 2025.

Researchers at Duke University Health System (Durham, NC, USA) utilized a novel genetic tool to analyze umbilical cord blood from 38 children who were part of the Newborn Epigenetics Study, a long-term birth cohort study. They focused on identifying changes in chemical tags—known as methyl groups—on the infants’ DNA that regulate gene activity. When these changes occur in critical areas of DNA, called imprint control regions, their effects can persist from fetal development into later life. The research team then compared the DNA changes with health data collected when the children reached ages 7 to 12. This data included body mass index, liver fat levels, alanine transaminase (ALT) — a marker of liver inflammation or damage, triglyceride levels, blood pressure, and waist-to-hip ratio.

The team identified several DNA regions where changes were linked to metabolic dysfunction later in childhood. For instance, alterations in the TNS3 gene were associated with liver fat, ALT levels, and waist-to-hip ratio, while changes in genes such as GNAS and CSMD1 were linked to blood pressure, waist-to-hip ratio, and ALT. Although the sample size was small, the researchers believe the findings are promising and warrant further exploration. A larger follow-up study is already underway. While these findings do not establish a direct cause-and-effect relationship between the genetic changes and disease, they highlight potential biological pathways that warrant further investigation.

“These epigenetic signals are laid down during embryonic development, potentially influenced by environmental factors such as nutrition or maternal health during pregnancy,” said co-author Cynthia Moylan, MD, associate professor of medicine, division of gastroenterology, at Duke University Health System. “If validated in larger studies, this could open the door to new screening tools and early interventions for at-risk children.”


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Portable POCT Blood Gas Analyzer
BD100
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment

Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.